Literature DB >> 1300751

[The humoral immunity indices of patients with malignant skin melanoma using the viral immunomodulator rigvir].

L S Glinkina, O G Heisele, R R Garklava, A J Muceniece.   

Abstract

The effect of a viral immunomodulator rigvir on humoral immunity was studied in patients with skin malignant melanoma. Peripheral blood levels of B-lymphocytes, IgA, G and M and circulating immune complexes were assayed and immunoglobulin/B-cell ratio (Ig/B) calculated. Preoperative treatment with rigvir brought the indexes of humoral immunity to normal. Response of melanoma patients to rigvir treatment was different from that seen in healthy subjects and was determined by the course of disease.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1300751

Source DB:  PubMed          Journal:  Vopr Onkol        ISSN： 0507-3758


  3 in total

Review 1.  The Role of Oncolytic Viruses in the Treatment of Melanoma.

Authors:  Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Oncol Rep       Date:  2018-08-25       Impact factor: 5.075

2.  Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.

Authors:  Simona Doniņa; Ieva Strēle; Guna Proboka; Jurgis Auziņš; Pēteris Alberts; Björn Jonsson; Dite Venskus; Aina Muceniece
Journal:  Melanoma Res       Date:  2015-10       Impact factor: 3.599

Review 3.  Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.

Authors:  Hani M Babiker; Irbaz Bin Riaz; Muhammad Husnain; Mitesh J Borad
Journal:  Oncolytic Virother       Date:  2017-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.